3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Myeloid
1
Conditions
Neuroblastoma
7
Lymphoma, B-Cell
5
Lymphoma
5
Rhabdoid Tumor
3
Neoplasms
3
Medulloblastoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pinealoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms, Germ Cell and Embryonal
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Ganglioneuroblastoma
2
Ependymoma
2
Enteropathy-Associated T-Cell Lymphoma
2
Brain Neoplasms
2
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Interventions
Magnetic Resonance Spectroscopy
9
Cyclophosphamide
7
X-Rays
6
Temozolomide
6
Specimen Handling
6
Phantoms, Imaging
6
Biopsy
6
Nuclear Medicine Department, Hospital
5
Etoposide
5
Nivolumab
4
Bevacizumab
4
Radiation
3
Irinotecan
3
Automobiles
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
lutetium Lu 177 dotatate
2
larotrectinib
2
ivosidenib
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
abemaciclib
2
Watchful Waiting
2
Radiotherapy
2
ONC206
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Ependymoma
×
etoposide phosphate
×
1 year
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled